847729-63-9

Usage

Uses

Used in Organic Synthesis:
(S)-tert-butyl 1-(4-cyanophenyl)ethylcarbaMate is used as a chiral auxiliary for introducing chirality into molecules, which is crucial for the development of enantiomerically pure compounds. This application is particularly important in the pharmaceutical industry, where the stereochemistry of a drug can significantly impact its efficacy and safety.
Used in Asymmetric Synthesis:
In the field of asymmetric synthesis, (S)-tert-butyl 1-(4-cyanophenyl)ethylcarbaMate is utilized as a reagent to facilitate the creation of chiral centers in target molecules. (S)-tert-butyl 1-(4-cyanophenyl)ethylcarbaMate's ability to induce chirality is valuable for producing enantiomerically enriched products, which are essential in various chemical and pharmaceutical applications.
Used as a Protecting Group:
(S)-tert-butyl 1-(4-cyanophenyl)ethylcarbaMate is used as a protecting group for alcohols, amines, and carboxylic acids during complex synthesis pathways. This function allows chemists to carry out selective reactions without affecting the protected functional groups, which can then be deprotected when needed, providing a strategic advantage in multi-step synthesis processes.
Used in Pharmaceutical Applications:
(S)-tert-butyl 1-(4-cyanophenyl)ethylcarbaMate has been studied for its potential use in the pharmaceutical industry, capitalizing on its unique chiral properties. Its ability to influence the stereochemistry of organic reactions can lead to the development of new drugs with improved efficacy and selectivity, ultimately benefiting patients and advancing medical treatments.

Upstream product

• 557-21-1 zinc(II) cyanide 
• 847728-89-6 (S)-tert-butyl (1-(4-bromophenyl)ethyl)carbamate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 773837-37-9 sodium cyanide 
• 1313367-04-2 [(S)-1-(4-Iodo-phenyl)-ethyl]-carbamic acid tert-butyl ester 
• 557-21-1 dicyanozinc 

Downstream Products

• 847729-65-1 [(1S)-1-(4-(2H-tetrazol-5-yl)phenyl)ethyl]amine hydrochloride 
• 1177316-44-7 (S)-4-(1-aminoethyl)benzonitrile hydrochloride 
• 1177316-44-7 (S)-4-(1-aminoethyl)benzonitrile hydrochloride 
• 36244-70-9 (S)-4-(1-aminoethyl)benzonitrile 
• 1097196-64-9 tert-butyl [(1S)-1-{4-[amino(hydroxyimino)methyl]phenyl}ethyl]carbamate 
• 916211-64-8 (S)-4-(1-aminoethyl)benzoic acid hydrochloride salt 
• 847729-64-0 tert-butyl [(1S)-1-(4-(2H-tetrazol-5-yl)phenyl)ethyl]carbamate 

Relevant academic research and scientific papers

BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE

The present disclosure relates to bifunctional compounds, which find utility as modulators of SMARCA2 or BRM (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a ligand that binds to the Von Hippel-Lindau E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

A novel series of potent and selective EP4 receptor ligands: Facile modulation of agonism and antagonism

A novel series of EP4 ligands, based on a benzyl indoline scaffold, has been discovered. It was found that agonism and antagonism in this series can be easily modulated by minor modifications on the benzyl group. The pharmacokinetic, metabolic

METALLOPROTEASE INHIBITORS

The present invention relates to amide containing aromatic MMP inhibiting compounds with a mono-amide heteroaromatic group, of formulas I and II:

HETEROBICYCLIC METALLOPROTEASE INHIBITORS

The present invention relates generally to heterobicyclic containing pharmaceutical agents, and in particular, to heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic metalloprotease inhibiting compounds that exhibit an increased potency in relation to currently known metalloprotease inhibitors.

Substituted bis-amide metalloprotease inhibitors

This invention relates to substituted bis-amide pyrimidine compounds of Formula (I), which are useful for the treatment of metalloprotease mediated diseases, in particular MMP-13 related diseases.

HETEROBICYCLIC METALLOPROTEASE INHIBITORS

The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP- 13 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP- 13 inhibitors.

PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS

This invention provides a compound of the formula (I): wherein A represents a phenyl group or the like: B represents an aryl or the like: E represents a 1,4-phenylene group; R1 and R2 independently represent a hydrogen atom or the li

COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS

The instant invention relates to a combination of an EP4-receptor antagonist and an alpha-2-delta ligand, and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof and their use in the treatment of pain, particularly inflammatory,